Author: Nicholls, John M
Title: The Battle Between Influenza and the Innate Immune Response in the Human Respiratory Tract Document date: 2013_3_29
ID: vyci1ho3_50
Snippet: IFNα has been shown as an effective control of hepatitis B and C in humans, particularly active HCV, in which IFNα has cured 98% of affected individuals. During the 2003 SARS outbreak in Toronto, IFN alfacon-1, a novel synthetic consensus IFN, showed clinical benefit in patients treated with steroids and IFN compared with those treated with steroids alone [85] . In guinea pigs and ferrets infected with H5N1 and seasonal influenza respectively, .....
Document: IFNα has been shown as an effective control of hepatitis B and C in humans, particularly active HCV, in which IFNα has cured 98% of affected individuals. During the 2003 SARS outbreak in Toronto, IFN alfacon-1, a novel synthetic consensus IFN, showed clinical benefit in patients treated with steroids and IFN compared with those treated with steroids alone [85] . In guinea pigs and ferrets infected with H5N1 and seasonal influenza respectively, IFN treatment resulted in reduced vi-ral titres and improved pulmonary pathology [86, 87] . There were promising results of intranasal administration of IFNα in preventing influenza infection in the 1980's but side-effects prevented the widespread adoption of this route of administration [88, 89] . Treatment with alfacon-1 of human ex vivo tissues infected with H1N1pdm and H5N1 showed it was able to reduce infection but IFN treatment post-exposure produced a less dramatic effect [90] . As this latter scenario is the one most likely to be encountered in clinical practice this implies that IFN use in the clinical setting may have only limited benefit.
Search related documents:
Co phrase search for related documents- administration route and clinical practice: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- administration route and clinical setting: 1, 2
- administration route and effective control: 1
- administration route and infection reduce: 1, 2
- administration route and influenza infection: 1, 2, 3
- administration route and intranasal administration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- administration route and post exposure: 1, 2
- administration route and SARS outbreak: 1
- administration route and seasonal influenza: 1
- administration route and vivo tissue: 1, 2
- affected individual and clinical practice: 1, 2, 3
- affected individual and effective control: 1
- affected individual and infection reduce: 1, 2
- clinical benefit and effective control: 1, 2, 3
- clinical benefit and infection reduce: 1, 2, 3
- clinical benefit and influenza infection: 1, 2, 3, 4, 5, 6, 7, 8
- clinical benefit and limit benefit: 1
- clinical benefit and post exposure: 1, 2, 3, 4, 5
- clinical benefit and SARS outbreak: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date